CNS Pharmaceuticals Inc.

Company Overview

Business Model: CNS Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases in neurology and oncology. The Company's primary revenue generation mechanism is expected to be through the successful development, regulatory approval, and commercialization of drug candidates, potentially via out-licensing or partnerships, as it currently has no products approved for commercial sale.

Market Position: The Company operates in the neurology and oncology therapeutic areas, which represent large, fast-growing, and scientifically dynamic sectors characterized by significant unmet medical needs. The global neurological therapeutics market exceeds $138 billion, and the global oncology therapeutics market is projected to reach $400 billion in the next decade. CNS Pharmaceuticals, Inc. faces intense competition from major pharmaceutical and biotechnology companies, many of which possess substantially greater financial, technical, manufacturing, marketing, and human resources.

Recent Strategic Developments:

• New Corporate Growth Strategy (March 11, 2026): The Company announced a new corporate growth strategy focused on building a high-value pipeline in neurology and oncology. This strategy involves a disciplined approach to identify, acquire, or in-license differentiated preclinical and clinical-stage assets with strong biological rationale, validated or emerging clinical data, and clear development and regulatory pathways. The Company prioritizes opportunities with near- to mid-term value inflection points, meaningful commercial potential, and relevance to its team’s expertise, while maintaining capital discipline.
• Executive Leadership Team Rebuilt (January 1, 2026, and March 2, 2026): Rami Levin, MBA, was appointed President & Chief Executive Officer on January 1, 2026. Subsequently, on March 2, 2026, the Company rebuilt its executive leadership team by appointing a new Chief Business Officer, Chief Financial Officer, Chief Medical Officer, and Chief Technology Officer to execute the new corporate strategy.
• Pivot from Glioblastoma Multiforme (March 11, 2026): As part of its new corporate strategy, the Company pivoted from its historical singular focus on glioblastoma multiforme (GBM).
• Out-licensing of Legacy Assets: The Company intends to explore out-licensing opportunities for its investigational compounds, TPI 287 and Berubicin, as they are not aligned with the new strategic direction.

Geographic Footprint: The Company's corporate headquarters is located in Houston, Texas. Its exclusive license agreement for TPI 287 covers the United States, Canada, Mexico, and Japan. Berubicin has Orphan Drug Designation in the United States. The Company has initiated a global asset search as part of its new strategy.

Legacy Product Portfolio

• TPI 287: An investigational chemotherapy agent (abeotaxane class) designed to penetrate the blood-brain barrier. It has been evaluated in multiple early-phase clinical studies involving over 300 patients across several oncology indications, including glioblastoma. A Phase 1/2 clinical study in recurrent glioblastoma, in combination with bevacizumab, demonstrated an objective response rate of approximately 54% and a disease control rate of approximately 92%. TPI 287 has Orphan Drug Designation from the FDA. The Company obtained exclusive rights to certain intellectual property related to TPI 287 in the United States, Canada, Mexico, and Japan through an Exclusive License Agreement with Cortice Biosciences, Inc. in July 2024. Existing TPI 287 patents will expire in 2028.
• Berubicin: An investigational anthracycline chemotherapy agent. Preclinical and early clinical studies suggested its capability to penetrate the blood-brain barrier. Phase 1 clinical trials in patients with recurrent malignant gliomas observed a disease control rate of approximately 44%. The Company conducted a randomized Phase 2 superiority clinical trial (CNS-201) comparing Berubicin to lomustine in recurrent glioblastoma, which did not meet its primary endpoint of showing superiority in overall survival. Berubicin has Orphan Drug Designation (granted June 10, 2020) and Fast Track Designation (granted July 24, 2021) from the FDA. The Company does not hold or license any patents related to Berubicin, with ODD constituting its primary intellectual property protection.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: Not applicable (no revenue)
• Operating Margin: Not applicable (no revenue)
• Net Margin: Not applicable (no revenue)

Investment in Growth:

• R&D Expenditure: $9.8 million (61.1% of total operating expenses)
• Capital Expenditures: $18,175
• Strategic Investments:
  • Acquisition of exclusive rights to TPI 287 intellectual property from Cortice Biosciences, Inc. (July 29, 2024), involving issuance of common stock with a fair value of $596,303 and potential future milestone payments and royalties.
  • Acquisition of Berubicin intellectual property and development data from Reata Pharmaceuticals (November 21, 2017).

Business Segment Analysis

The Company manages its operations as a single segment for the purpose of assessing performance and making operating decisions.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: $(2,043) (due to stock split rounding)
• Dividend Payments: $0
• Dividend Yield: 0%
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position:

• Cash and Equivalents: $7.2 million (as of December 31, 2025)
• Total Debt: $328,571 (as of December 31, 2025)
• Net Cash Position: $6.9 million (as of December 31, 2025)
• Debt Maturity Profile: A short-term note payable of $360,197 (bearing 8.24% interest) was entered into on November 8, 2025, with the final payment due on October 8, 2026.

Cash Flow Generation:

• Operating Cash Flow: $(13.8) million
• Free Cash Flow: Not explicitly calculated, but negative given operating cash flow and minimal capital expenditures.

Operational Excellence

Production & Service Model: The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturers for the production of active pharmaceutical ingredients (API) and the formulation of drug product for its preclinical development and clinical trials.

Supply Chain Architecture: Key Suppliers & Partners:

• Contract Manufacturers: Third-party manufacturers are utilized for API and drug product.
• Contract Research Organization (CRO): A third-party CRO is used to manage clinical studies, including the global trial of Berubicin.

Facility Network:

• Manufacturing: Relies entirely on third-party contract manufacturers.
• Research & Development: R&D activities are managed internally and through third-party service providers; no specific R&D centers are disclosed.
• Distribution: Not applicable as no products are commercialized.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Neurology and oncology are among the largest, fastest-growing, and most scientifically dynamic sectors in biopharmaceuticals, driven by aging demographics, advancements in biological understanding, biomarker discovery, and enhanced diagnostic capabilities.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Major Pharmaceutical Companies: AstraZeneca, Bristol Myers Squibb, Roche, Merck & Co., Pfizer, Eli Lilly, Johnson & Johnson, Biogen, UCB, Novartis, AbbVie, Eisai. These companies have extensive oncology and/or CNS pipelines and significant infrastructure.
• Biotechnology Companies: Numerous mid-size and emerging biotechnology companies actively developing oncology and neurology programs across various modalities.
• Asset Acquirers/Licensors: Companies such as Roivant, Ligand Pharmaceuticals, Fortress Biosciences, and other private and public companies that also seek to acquire or in-license assets.

Competitive Response Strategy: The Company's strategy is to identify and secure assets that are novel and differentiated, with the potential to be best-in-class, by leveraging its executive team's expertise in neurology and oncology. This includes advancing product candidates through clinical development efficiently, establishing intellectual property positions, and entering into strategic partnerships or licensing arrangements.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The Company faces significant competition from companies with substantially greater financial, technical, manufacturing, marketing, and human resources. Competitors may develop safer, more effective, or less costly products, rendering the Company's product candidates non-competitive or obsolete. Technology Disruption: Rapid technological advancements in the biotechnology and pharmaceutical industries pose a risk that the Company's technologies or product candidates could become obsolete or less competitive.

Operational & Execution Risks

Supply Chain Vulnerabilities: The Company is entirely dependent on third-party contract manufacturers for API and drug product. Risks include inability to enter into or maintain manufacturing agreements, breaches of agreements, termination or nonrenewal of agreements, failure to meet specifications or cGMP standards, and inability to find alternative manufacturers, which could delay or prevent commercialization. Capacity Constraints: If contract manufacturers fail to deliver required commercial quantities on a timely basis, the Company may be unable to meet demand for its products.

Financial & Regulatory Risks

Market & Financial Risks: The Company has never been profitable, has no products approved for commercial sale, and has not generated any revenue from product sales. It has incurred significant operating losses and expects to continue to incur losses. Substantial additional funding is required to execute its new corporate strategy, and there is no assurance that such funding will be available on acceptable terms, or at all. The Company's auditors have expressed substantial doubt about its ability to continue as a going concern. Regulatory & Compliance Risks: The development and approval of pharmaceutical products are subject to extensive, lengthy, expensive, and uncertain regulation by the FDA and international authorities. Product candidates may fail clinical trials, have undesirable side effects, or not receive regulatory approval. Delays in clinical trials, manufacturing challenges, or non-compliance with cGMP requirements could significantly impact development timelines and costs.

Geopolitical & External Risks

Catastrophic Events: Suppliers may lack adequate measures to recover from catastrophic events (e.g., weather, geologic events, epidemics, acts of war, terrorism, nationalization), which could disrupt the supply chain and affect the Company's ability to meet critical timelines. Cybersecurity: The Company relies on information technology and third-party SaaS providers, making it susceptible to cyber-based attacks, network security breaches, service interruptions, or data corruption. Such incidents could cause operational failures, compromise sensitive data, and result in significant financial damages or litigation.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas: The Company's current R&D focus is on identifying, acquiring, or in-licensing differentiated preclinical and clinical-stage assets in neurology and oncology. Innovation Pipeline: The Company is actively evaluating opportunities aligned with its new strategic criteria. Its legacy assets, TPI 287 and Berubicin, are being explored for out-licensing.

Intellectual Property Portfolio:

• Patent Strategy: Existing U.S. and foreign patents for TPI 287 will expire in 2028. The Company does not hold or license any patents related to Berubicin, with its Orphan Drug Designation (ODD) serving as the primary intellectual property protection. The Company is exploring the possibility of filing additional patent applications for both TPI 287 and Berubicin to extend protections, but there is no assurance of success.
• Licensing Programs: The Company holds an exclusive license for TPI 287 from Cortice Biosciences, Inc. covering the United States, Canada, Mexico, and Japan. It acquired all intellectual property and development data regarding Berubicin from Reata Pharmaceuticals.
• IP Litigation: The Company is not currently involved in any material litigation related to intellectual property.

Technology Partnerships:

• Strategic Alliances: Cortice Biosciences, Inc. (exclusive license for TPI 287). Reata Pharmaceuticals (acquisition of Berubicin IP).

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The Company underwent a significant rebuilding of its executive leadership team in the first quarter of 2026, with new appointments for CEO, CFO, CMO, CBO, and CTO, to align with and execute its new corporate strategy.

Human Capital Strategy

Workforce Composition:

• Total Employees: 8 full-time employees (as of March 31, 2026). Five of these employees are members of the executive team.
• Skill Mix: The executive team brings diverse experience in clinical development, regulatory affairs, chemistry, manufacturing and controls (CMC), business development, finance, capital markets, commercialization, and company transformation.

Talent Management: Acquisition & Retention: The Company's human capital objectives include identifying, recruiting, retaining, incentivizing, and integrating existing and new employees, advisors, and consultants to support its operations and pipeline expansion.

Regulatory Environment & Compliance

Regulatory Framework: The Company's product candidates are subject to extensive regulation by government authorities in the United States (FDA) and other countries. This includes regulations governing research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring, and reporting. The process of obtaining regulatory approvals is lengthy, expensive, and uncertain. Industry-Specific Regulations: Compliance with the Federal Food, Drug, and Cosmetic Act, Good Manufacturing Practices (cGMP), and Good Clinical Practices (GCP) is required. International Compliance: The Company is subject to foreign regulations for clinical trials and commercial sales and distribution, including European Union marketing authorization procedures.

Legal Proceedings: The Company is not currently a party to any pending legal actions that it believes could have a material effect on its business, financial condition, results of operations, or cash flows.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: 0% for the years ended December 31, 2025, and 2024, primarily due to a full valuation allowance against deferred tax assets.
• Net Operating Losses: As of December 31, 2025, the Company has approximately $50.6 million in net operating loss carryforwards. Approximately $200,000 of these NOLs will begin to expire in 2037, while the remaining post-2017 NOLs may be carried forward indefinitely.
• Tax Reform Impact: The Tax Reform Act of 1986 limits the use of net operating loss carryforwards in certain situations involving changes in company stock ownership.

Insurance & Risk Transfer

Risk Management Framework: The Company does not carry insurance for all categories of risk that its business may encounter and there is no assurance that any secured insurance coverage will be sufficient to protect its operations from significant potential liability.